Myleran (Busulfan)

Busulfan, the active ingredient in Myleran, is an alkylating agent presented as an oral solution for oral administration. It is employed in the treatment of chronic myelogenous leukemia and as part of conditioning regimens prior to allogeneic bone marrow transplantation, targeting rapidly dividing malignant cells and supportive care protocols.

GNH USA supplies Myleran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable sourcing for clinicians and procurement teams across regulated markets and ensuring compliance with local regulatory requirements.

Busulfan is an alkylating antineoplastic agent used in hematologic malignancies and transplant conditioning.

Chronic myelogenous leukemia: reduces leukemic cell proliferation as part of chemotherapy protocols. Bone marrow transplantation conditioning: eradicates residual disease and creates immunosuppression to facilitate engraftment.

Busulfan may be associated with a range of adverse reactions, varying from mild to potentially life‑threatening.

Common Side Effects: - Nausea and vomiting - Oral mucositis - Alopecia - Myelosuppression (decreased blood counts)

Serious or Rare Side Effects: - Pulmonary fibrosis - Hepatic veno‑occlusive disease - Seizures - Severe bone marrow failure

When using Busulfan, clinicians should observe several safety measures.

Blood count monitoring: Perform regular CBC to detect myelosuppression. Liver function assessment: Check hepatic enzymes before and during therapy. Pulmonary evaluation: Baseline and periodic lung function tests are recommended. Pregnancy avoidance: Do not use in pregnant patients; discuss contraception. Dose adjustment in hepatic impairment: Reduce dose or increase monitoring as needed. Store at ambient temperature: Keep in original container, protect from moisture and light.

Busulfan interacts with several medicines that may alter its efficacy or toxicity.

Major Interactions (Avoid): - Azathioprine: increased risk of severe myelosuppression. - Cyclophosphamide: additive bone marrow toxicity. - Phenytoin: may reduce Busulfan plasma concentrations.

Moderate Interactions (Monitor Closely): - Acetaminophen: potential increase in Busulfan exposure. - Fluconazole (and other azole antifungals): may raise Busulfan levels. - Hormonal contraceptives: possible reduction in effectiveness.